Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.71 +2.34 (+2.88%)
Official Closing Price Updated: 7:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma. 
Via Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
NYSE:MRK: good value for what you're paying.
MERCK & CO. INC. (NYSE:MRK) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
Via The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Competitor Analysis: Evaluating Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
Via Benzinga
Where Will Merck Stock Be in 5 Years?
This drugmaker faces a key test in the next several years. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Merck & Co Unusual Options Activity
Via Benzinga
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. 
Via MarketBeat
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1... 
Via Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
The company also unveiled 10-year test results for Keytruda in advanced melanoma patients. 
Via Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
MarketBeat Week in Review – 9/9 - 9/13
Markets were mostly positive this week as benign inflation numbers did nothing to dampen expectations that the Federal Reserve will cut interest rates 
Via MarketBeat
Topics Economy
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,... 
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday. 
Via Investor's Business Daily
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
Via MarketBeat
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
From Merck & Co., Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.